Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Trial Details

NCT ID
NCT06239194
Phase
PHASE1 / PHASE2
Sponsor
ModeX Therapeutics, An OPKO Health Company
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • MDX2001
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Miami, Florida, United States|25.77427,-80.19366
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients must be ≥ 18 years of age
  • Histologically or cytologically confirmed diagnosis of metastatic solid tumors
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • All patients should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →